Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease

Published:2022-08-09 Issue:10 Volume:117 Page:1153-1162
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sanguinis

Author:

Kriván Gergely¹,Borte Michael²,Harris James B.³,Lumry William R.⁴,Aigner Silke⁵,Lentze Stephan⁵,Staiger Christiane⁵^ORCID

Affiliation:

1. Department of Pediatric Hematology and Stem Cell Transplantation Central Hospital of Southern Pest ‐ National Institute of Hematology and Infectious Diseases Budapest Hungary

2. ImmunDeficiencyCenter Leipzig (IDCL) at Klinikum St. Georg gGmbH Leipzig Germany

3. The South Bend Clinic South Bend Indiana USA

4. AARA Research Center Dallas Texas USA

5. Biotest AG Dreieich Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.13337

Reference22 articles.

1. Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network

2. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

3. Primary Immune Deficiencies - Principles of Care

4. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders

5. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PharmaNews;Transfusion Medicine and Hemotherapy;2023

2. PharmaNews;Oncology Research and Treatment;2023

3. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia;Transfusion Medicine;2022-11-30

4. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children;Journal of Clinical Immunology;2022-11-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3